Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Friday, 30'th Jan 2026
SAN FRANCISCO, Jan. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on January 21, 2026, the Organization and Compensation Committee of Nektar's Board of Directors g
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
10:00am, Thursday, 22'nd Jan 2026
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to
Emerald Advisers LLC Takes Position in Nektar Therapeutics $NKTR
04:53am, Thursday, 22'nd Jan 2026
Emerald Advisers LLC bought a new stake in Nektar Therapeutics (NASDAQ: NKTR) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institution
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
04:20pm, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors are a
Nektar.io Introduces DIRT: Materials Management for the Construction Industry
06:58pm, Thursday, 15'th Jan 2026
Edmonton, Alberta--(Newsfile Corp. - January 15, 2026) - Nektar.io, located at 14420 154 Ave NW, Edmonton, Alberta, T6V 0K8, Canada, a provider of operational software for the construction industry to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
10:00am, Thursday, 15'th Jan 2026
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
04:28pm, Tuesday, 13'th Jan 2026
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors
Nektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200 Day Moving Average – Here’s What Happened
03:08am, Friday, 09'th Jan 2026
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) shares passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $43.51 and traded as high as $
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
10:00am, Thursday, 08'th Jan 2026
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
09:46am, Wednesday, 07'th Jan 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
11:50am, Tuesday, 06'th Jan 2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
10:00am, Thursday, 01'st Jan 2026
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR
12:40pm, Tuesday, 30'th Dec 2025
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
03:35am, Friday, 26'th Dec 2025
Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
11:56am, Wednesday, 24'th Dec 2025
MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
